In the present review, we try to critically evaluate the two faces of the macrophages and their roles in relation to gene alteration in some inflammatory conditions. The pros- and cons of each type of macrophage in immunologic outcomes are discussed.
If “Diversity is the rule of nature”, macrophages have proven to be its obedient followers. A cell type that was classically considered to be activated by Interferon-γ, under the influence of TH-1 type of response and a well-accepted warrior of cellular immunity to the intracellular pathogens is not as simple as once considered. Past decade has revolutionized this notion with the advent of TH-2 influenced alternatively activated macrophages, now established as wound repairing and tissue regenerating.
Literature survey was done to present a detailed study on this macrophage dichotomy and its relevance to immune disorders via expression of some critical genes, nuclear factor kappa-light-chain-enhancer of activated B cells, peroxisome proliferator-activated receptors and SH2-containing inositol-5′-phosphatase 1, highly implicated in a myriad of immunological emergencies like inflammation, insulin resistance, wound healing, cancer, etc.
The evaluation of macrophage dichotomy in these disorders may prove to be the first step towards the formulation of innovative therapeutic approaches.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Similar content being viewed by others
Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72:621–7.
Yona S, Kim K-W, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91.
Lefe`vr L, Gale`s A, Olagnier D, et al. PPARγ Ligands switched High Fat Diet-Induced Macrophage M2b polarization toward M2a Thereby Improving Intestinal Candida Elimination. PLoS ONE. 2010;9:e12828.
Fujisaka S, Usui I, Bukhari A, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes. 2009;58:2574–82.
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.
Chakkalath HR, Titus RG. Leishmania major-parasitized macrophages augment Th2-type T cell activation. J. Immunol. 1994;153:4378.
Andrew DC, Emma LB, John AH. The phenotype of inflammatory macrophages is stimulus dependent: implications for the nature of the inflammatory response. J Immunol. 2003;171:4816–23.
Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.
Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.
Fernando M, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.
Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
Fernando M, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Rep. 2014;6:13.
Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86.
Nathan CF, Jr Hibbs J B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 1991;3:65.
Williams-Ashman HG, Canellakis ZN. Polyamines in mammalian biology and medicine. Perspect Biol Med. 1979;22:421.
Wu G, Jr Morris S M. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1.
Charles D. Mills, Kristi Kincaid, Jennifer M. M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J Immunol. 2000;164:6166–73.
Bourlier V, Girard AZ, Miranville A, et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation. 2008;117:806–15.
Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006;116:115–24.
Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Riko K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006;116:1494–505.
Kamei N, Tobe K, Suzuki R. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006;281:26602–14.
Ito A, Suganami T, Yamauchi A, et al. Role of CC chemokines receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. J Biol Chem. 2008;283:35715–23.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993;268:26055–8.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.
Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001;7:1138–43.
Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–7.
Pierce JW, Read MA, Ding H, et al. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 1996;156:3961–9.
Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998;396:77–80.
Carey NL, Stephanie MDY, Jennifer LB, Alan RS. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes. 2007;56:16–23.
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610–4.
Mantovani Alberto. Inflammation and cancer: the macrophage connection. Medicina. 2007;67:32–4.
Geldhof AB, Van Ginderachter JA, Liu Y, Noël W, Raes G, De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood. 2002;100(12):4049–58.
Schutyser E, Struyf S, Proost P, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. JBC. 2002;277:24584–93.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–52.
Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.
Jeffrey WP. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.
Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Jr Holmes D R, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022–9.
Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation. 2002;106:1904–5.
Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–21.
Redd MJ, Cooper L, Wood W, Stramer B, Martin P. Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci. 2004;359:777–84.
Eming SA, Daniel AM, Ronald G, et al. Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum Gene Ther. 1998;9(4):529–39.
Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med. 2005;11:183–90.
Sinha S, Perdomo G, Brown NF, O’Doherty RM. Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B. J Biol Chem. 2004;279:41294–301.
Monick MM, Robeff PK, Butler NS, et al. Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem. 2002;277:32992.
Sly LM, Ho V, Antignano F, et al. The role of SHIP in macrophages. Front Biosci. 2007;12:2836–48.
Tzameli I, Fang H, Ollero M, et al. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem. 2004;279:36093–102.
Ho VW, Sly LM. Derivation and characterization of murine alternatively activated (M2) macrophages. Methods Mol Biol. 2009;531:173–85.
Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new Insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551–8.
Eibl G. The role of PPAR-γ and its interactions with COX-2 in pancreatic cancer. PPAR research. 2008;2008:326915.
Han YP, Tuan TL, Wu H, et al. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa) B mediated induction of MT1-MMP. J Cell Sci. 2001;114:131–9.
Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655–63.
Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.
Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.
Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10:233.
Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB. PNAS. 2008;106(35):14978–83.
Zhang Z, Li X, Lv W, et al. Ginsenoside Re Reduces Insulin Resistance through Inhibition of c-Jun NH2-Terminal Kinase and Nuclear Factor- Κb. Mol Endocrinol. 2008;22:186–95.
Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. Clin Invest. 2003;112:1796–808.
Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med. 2007;262:408–14.
Fong CHY, Didierlaurent A, et al. An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation. J Exp Med. 2008;205(6):1269–76.
Powell DJ, Turban S, Gray A, et al. Intracellular ceramide synthesis and protein kinase Cζ activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J. 2004;382:619–29.
Sabin MA, Stewart CE, Crowne EC, et al. Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intra myocellular lipid. J Cell Physiol. 2007;211:244–52.
Jove M, Planavila A, Laguna JC, Vazquez-Carrera M. Palmitate induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology. 2005;146:3087–95.
Jove M, Planavila A, Sanchez RM, et al. Palmitate induce tumor necrosis factor-a expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kB activation. Endocrinology. 2006;147:552–61.
Weigert C, Brodbeck K, Staiger H, Kaush C, Machicao F, Haring H, et al. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteosomedependent activation of nuclear factor-kB. J Biol Chem. 2004;279:23942–52.
Perkins ND. Oncogenes, tumor suppressors and p52 NF-kB. Oncogene. 2003;22:7553–6.
Kieran M, Blank V, Logeat F, et al. The DNA binding subunit of NF-kB is identical to factor KBF1 and homologous to the rel oncogene product. Cell. 1990;62:1007–18.
Ghosh S, Gifford AM, Riviere LR, et al. Cloning of the p50 DNA binding subunit of NF-kB: homology to rel and dorsal. Cell. 1990;62:1019–29.
Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999;18:6925–37.
Perkins ND. NF-κB: tumor promoter or suppressor? Trends Cell Biol. 2004;14:64–9.
Pahl HL. Activators and target genes of Rel/NF-kB transcription factors. Oncogene. 1999;18:6853–66.
Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kB in p53-mediated programmed cell death. Nature. 2000;404:892–7.
Rocha S, Campbell KJ, Perkins ND. p53 andMdM2 independent repression of NF-kB transactivation by the ARF tumour suppressor. Mol Cell. 2003;12:15–25.
Rauh MJ, Sly LM, Kalesnikoff J, et al. The role of SHIP1 in macrophage programming and activation. Biochem Soc Trans. 2004;32:5.
Sly LM, Rauh MJ, Kalesnikoff J, et al. SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol. 2003;31:1170–81.
Maxwell MJ, Yuan Y, Anderson KE, et al. SHIP-1 and lyn kinase negatively regulate integrin alpha IIb beta3 signaling in platelets. J Biol Chem. 2004;279:32196–204.
Kalesnikoff J, Lam V, Krystal G. SHIP represses mast cell activation and reveals that IgE alone triggers signaling pathways which enhance normal mast cell survival. Mol Immunol. 2002;38:1201–6.
Lam V, Kalesnikoff J, Lee CW, Hernandez-Hansen V, et al. IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor. Blood. 2003;102:1405–13.
Giuriato S, Pesesse X, Bodin S, et al. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roes in the control of phosphatidylinositol 3,4,5-trisphosphate levels. Biochem J. 2003;376:199–207.
Gardai S, Whitlock BB, Helgason C, et al. Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem. 2002;277:5236–46.
Fibach E. Involvement of phosphatases in proliferation, maturation, and hemoglobinization of developing erythroid cells. J Signal Transduc. 2011;2011:860985.
Sly LM, Rauh MJ, Kalesnikoff J, et al. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity. 2004;21:227–39.
Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002;277:32124.
Huang XL, Wang YJ, Yan JW, et al. Role of anti-inflammatory cytokines IL-4 and IL-13 in systemicsclerosis Inflamm. Res. 2015;64:151–9.
Rauh MJ, Ho V, Pereira C, et al. SHIP represses the generation of alternatively activated macrophages. Immunity. 2005;23:361–74.
Hamilton MJ, Ho VW, Kuroda E, et al. Role of SHIP in cancer. Exp Hematol. 2011;39:2–3.
Jiang BH, Liu LZ. PI3 K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 2009;102:19–65.
Ho VW, Hamilton MJ, Kuroda E, et al. Tumour-associated macrophages. Biomed Life Sci. 2012;3:135–51.
Costinean S, Sandhu SK, Pedersen IM, et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009;114:1374–82.
Lo TC, Barnhill LM, Kim Y, et al. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk. 2009;33:1562–6.
O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 2009;106:7113–8.
Pedersen IM, Otero D, Kao E, et al. Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas. EMBO Mol Med. 2009;1:288–95.
Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114:3265–75.
Marx N, Bourcier T, Sukhova G, et al. PPARg activation in human endothelial cells increases plasminogen activator inhibitor type-I expression. Arterioscler Thromb Vasc Biol. 1999;19:546–51.
Inoue I, Shino K, Noji S, et al. Expression of peroxisome proliferator-activated receptor a (PPARa) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998;246:370–4.
Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–50.
Fajas L, Auboeuf D, Raspé E, et al. The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem. 1997;272(18):779–89.
Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full anti-diabetic effects of thiazolidinediones. J Clin Investig. 2007;117:1658–69.
Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–4.
Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94:4318–23.
McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR gamma agonist. Proc Natl Acad Sci USA. 2003;100:131–6.
Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82.
Lazar MA. PPAR gamma, 10 years later. Biochimie. 2005;87:9–13.
Han KH, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator activated receptor-ϒ. J Clin Invest. 2000;106:793–802.
Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation. 2006;114:807–19.
Chawla A, Barak Y, Nagy L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7:48–52.
Spiegelman BM. PPAR-γ Adipogenic Regulator and Thiazolidinedione Receptor. Diabetes. 1998;47:507–14.
Nagai S, Shimizu C, Taniguchi UMS, et al. Identification of a function peroxisome proliferator-activated receptor responsive element within the murine perilipin gene. Endocrinology. 2004;145:2346–56.
Guan HP, Ishizuka T, Chui PC, et al. Corepressors selectively control the transcriptional activity of PPAR gamma in adipocytes. Genes Dev. 2005;19:453–61.
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPAR gamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116–20.
Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab. 2006;17:321–7.
Yerly-Motta V, Contassot E, Pavy JJ, et al. Expression of cyclins and cdks throughout murine carcinogenesis Cell. Mol Biol. 1999;45:1217–28.
Peters JM, Aoyama T, Cattley RC, et al. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis. 1998;19:1989–94.
Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803.
Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058–61.
Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4:1046–52.
Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol. 2005;85:194–202.
Responsible Editor: Graham R. Wallace.
About this article
Cite this article
Bashir, S., Sharma, Y., Elahi, A. et al. Macrophage polarization: the link between inflammation and related diseases. Inflamm. Res. 65, 1–11 (2016). https://doi.org/10.1007/s00011-015-0874-1